|
Valoración DCF de Altimmune, Inc. (ALT) |
Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
Predeterminadas Para Un Uso Rápido Y Eficiente
Compatible con MAC / PC, completamente desbloqueado
No Se Necesita Experiencia; Fáciles De Seguir
Altimmune, Inc. (ALT) Bundle
Ya sea que sea un inversor o analista, esta calculadora DCF (ALT) es su recurso de referencia para una valoración precisa. Equipado con datos reales de Altimmune, Inc., puede ajustar las previsiones y observar los efectos en tiempo real.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.2 | 4.4 | -.1 | .4 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -46.12 | -101.54 | -726.47 | -95.31 | -85.36 | -85.36 | -85.36 | -85.36 | -85.36 |
| EBITDA | -54.2 | -96.5 | -84.4 | -87.9 | -94.8 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -661.62 | -2188.98 | 124120.59 | -20642.02 | -474060 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | .4 | .6 | .5 | .5 | .2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 5.24 | 12.49 | -735.29 | 111.97 | 1190 | 23.55 | 23.55 | 23.55 | 23.55 | 23.55 |
| EBIT | -54.6 | -97.1 | -84.9 | -88.4 | -95.1 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -666.86 | -2201.47 | 124855.88 | -20753.99 | -475250 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 215.9 | 190.3 | 184.9 | 197.8 | 131.9 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | -.3 | .0 | .7 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 12.4 | .4 | 2.5 | 4.9 | 3.1 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 151.17 | 9.73 | -3736.76 | 1139.2 | 15585 | 41.95 | 41.95 | 41.95 | 41.95 | 41.95 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payable | .6 | 2.0 | 4.8 | 2.1 | .2 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 7.48 | 46.12 | -7064.71 | 485.92 | 1055 | 30.72 | 30.72 | 30.72 | 30.72 | 30.72 |
| Capital Expenditure | -.3 | -12.3 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -4.18 | -279.18 | 185.29 | -11.03 | 0 | -23.04 | -23.04 | -23.04 | -23.04 | -23.04 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -49.2 | -97.1 | -84.7 | -88.4 | -95.1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -60.8 | -95.5 | -83.7 | -93.0 | -94.9 | 2.9 | .0 | .0 | .0 | .0 |
| WACC, % | 6.69 | 6.69 | 6.69 | 6.69 | 6.69 | 6.69 | 6.69 | 6.69 | 6.69 | 6.69 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 2.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 3 | |||||||||
| Net Debt | -35 | |||||||||
| Equity Value | 38 | |||||||||
| Diluted Shares Outstanding, MM | 71 | |||||||||
| Equity Value Per Share | 0.53 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Pre-filled financial data for Altimmune, Inc. (ALT) to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model tailored to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, validating strategies, and enhancing efficiency.
Key Features
- Comprehensive ALT Data: Pre-filled with Altimmune’s historical financials and future projections.
- Fully Customizable Inputs: Adjust revenue growth, profit margins, discount rates, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Create multiple forecast scenarios to evaluate different valuation outcomes.
- User-Friendly Design: Simple, structured, and tailored for both professionals and beginners.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Altimmune data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Altimmune’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose Altimmune, Inc. (ALT) Calculator?
- Save Time: Quickly access a pre-built DCF model tailored for Altimmune, Inc. (ALT) without starting from scratch.
- Enhance Precision: Utilize accurate financial data and formulas to minimize valuation errors.
- Fully Customizable: Adjust the model to align with your specific assumptions and forecasts regarding Altimmune, Inc. (ALT).
- User-Friendly: Intuitive charts and outputs simplify the analysis of results.
- Endorsed by Professionals: Crafted for experts who prioritize accuracy and functionality in their evaluations.
Who Should Use This Product?
- Investors: Accurately assess Altimmune, Inc.'s (ALT) fair value prior to making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis tailored to Altimmune, Inc. (ALT).
- Consultants: Efficiently modify the template for valuation reports concerning Altimmune, Inc. (ALT) for clients.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies in the biotech sector.
What the Template Contains
- Pre-Filled Data: Includes Altimmune, Inc.'s historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Altimmune, Inc.'s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.